Posted by Michael Wonder on 08 Oct 2017
Turnbull government subsidy gives hope to cancer sufferers
9 October 2017 - A breakthrough leukaemia and lymphoma drug that normally costs $187,000 per treatment will become easily affordable under a new $460 million Turnbull government subsidy.
Ibrutinib, known as Imbruvica, will cost patients $38.80 a script – or $6.30 for concessional patients - once it is listed on the Pharmaceutical Benefits Scheme from December 1.
The drug will be available to all eligible patients with relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma.
